AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Jan 31, 2025
30604_dirs_2025-01-30_70c75299-4fb1-4d56-9b88-f1dcc59bc8f6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-01-28
Reporting Person: STEPHENSON BRIAN C (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-28 | Common Stock | M | 68000 | $17 | Acquired | 161758 | Direct |
| 2025-01-28 | Common Stock | S | 68000 | $36.2906 | Disposed | 93758 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-28 | Stock Option (right to buy) | $17 | M | 68000 | Disposed | 2029-06-26 | Common Stock (68000) | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2: Represents the weighted average sale price of the shares sold from $35.75 to $36.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.